“AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D. The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.
‘We are honored to have these esteemed and accomplished scientific and clinical leaders join AltPep’s Advisory Board,’ said Valerie Daggett, Ph.D., Founder and CEO of AltPep. ‘These individuals have each made foundational contributions to the field of neurodegenerative diseases. Their depth of expertise, together with the contributions of our current advisors, will be critical in advancing the development of our unique platform for early detection and treatment of Alzheimer’s disease and other amyloid diseases.’“